Targeting angiogenesis for the treatment of prostate cancer

Por Antonarakis, Emmanuel S, Carducci, Michael A
Publicado em 2012

Future Directions in Castrate-Resistant Prostate Cancer Therapy

Por Antonarakis, Emmanuel S., Carducci, Michael A.
Publicado em 2010

Combining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects

Por Antonarakis, Emmanuel S, Carducci, Michael A
Publicado em 2010

Use of androgen deprivation therapy in prostate cancer: indications and prevalence

Por Connolly, Roisin M, Carducci, Michael A, Antonarakis, Emmanuel S
Publicado em 2012

Novel targeted therapeutics for metastatic castration-resistant prostate cancer

Por Antonarakis, Emmanuel S., Carducci, Michael A., Eisenberger, Mario A.
Publicado em 2009

Acetylation and Histone Deacetylase Inhibitors in Cancer

Por Kortenhorst, Madeleine S. Q., Carducci, Michael A., Shabbeer, Shabana
Publicado no Cell Oncol (2006)

Management of bone metastases in refractory prostate cancer – role of denosumab

Por Paller, Channing J, Carducci, Michael A, Philips, George K
Publicado em 2012

Bone-targeting agents in prostate cancer

Por Suzman, Daniel L., Boikos, Sosipatros A., Carducci, Michael A.
Publicado em 2014

Contemporary Experience With Ketoconazole in Patients With Metastatic Castration-Resistant Prostate Cancer: Clinical Factors Associated With PSA Response and Disease Progression

Por Keizman, Daniel, Huang, Peng, Carducci, Michael A., Eisenberger, Mario A.
Publicado em 2011

Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

Por Kanarek, Norma F, Kanarek, Marty S, Olatoye, Dare, Carducci, Michael A
Publicado em 2012

Role of Immunotherapy for Renal Cell Cancer in 2011

Por George, Saby, Pili, Roberto, Carducci, Michael A., Kim, Jenny J.
Publicado em 2011

WHAT CAN I DO? RECOMMENDATIONS FOR RESPONDING TO ISSUES IDENTIFIED BY PATIENT-REPORTED OUTCOMES ASSESSMENTS USED IN CLINICAL PRACTICE

Por Hughes, Elizabeth F., Wu, Albert W., Carducci, Michael A., Snyder, Claire F.
Publicado em 2012

Fenugreek: a naturally occurring edible spice as an anticancer agent

Por Shabbeer, Shabana, Sobolewski, Michelle, Kachhap, Sushant, Davidson, Nancy, Carducci, Michael A., Khan, Saeed
Publicado em 2009

Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer

Por Franke, Ryan M., Carducci, Michael A., Rudek, Michelle A., Baker, Sharyn D., Sparreboom, Alex
Publicado em 2010

Progression of Prostate Carcinogenesis and Dietary Methyl Donors: Temporal Dependence

Por Shabbeer, Shabana, Williams, Simon A., Simons, Brian W., Herman, James G., Carducci, Michael A.
Publicado em 2011

Recent Time Trends in the Epidemiology of Stage IV Prostate Cancer in the United States: Analysis of Data From the Surveillance, Epidemiology, and End Results Program*

Por Cetin, Karynsa, Beebe-Dimmer, Jennifer L., Fryzek, Jon P., Markus, Richard, Carducci, Michael A.
Publicado no Urology (2009)

Changes in PSA Kinetics Predict Metastasis-Free Survival in Men with PSA-Recurrent Prostate Cancer Treated with Non-Hormonal Agents: Combined Analysis of 4 Phase II Trials

Por Antonarakis, Emmanuel S., Zahurak, Marianna L., Lin, Jianqing, Keizman, Daniel, Carducci, Michael A., Eisenberger, Mario A.
Publicado em 2012

Prostate Cancer Update: Advanced Disease

Por Carducci, Michael A, Crawford, E. David, Higano, Celestia S, Mendoza-Valdes, Arturo, Petrylak, Daniel P, Schalken, Jack
Publicado em 2003

Hormone-Refractory Prostate Cancer: New Horizons

Por Petrylak, Daniel P, Abrahamsson, Per-Anders, Bartsch, Georg, Carducci, Michael A, Small, Eric J, Wilding, George
Publicado em 2003

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastati...

Por Keizman, Daniel, Ish-Shalom, Maya, Huang, Peng, Eisenberger, Mario A., Pili, Roberto, Hammers, Hans, Carducci, Michael A.
Publicado em 2011